DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans.

Author(s): Samonis G, Thomakos N, Liakakos T, Macheras A, Mandrekas D, Kanavaki S, Bafaloukos D, Maraki S

Affiliation(s): Division of Medicine, University of Crete, Heraklion, Crete, Greece.

Publication date & source: 2001-09, Chemotherapy., 47(5):350-3.

Publication type: Clinical Trial; Randomized Controlled Trial

BACKGROUND: The study evaluated the effects of cefepime and meropenem on the gastrointestinal (GI) colonization of surgical patients by Candida albicans. PATIENTS AND METHODS: Twenty adult surgical patients who received intravenously either of these antibiotics as monotherapy for the treatment of an existing infection were studied prospectively. Ten patients received cefepime (2.0 g twice a day), and another ten meropenem (1.0 g every 8 h) for 7 days. Quantitative stool cultures for C. albicans were performed immediately before, at the end, and 1 week after the end of antibiotic treatment. RESULTS: Both antibiotics increased the GI colonization of patients by Candida. Meropenem caused a higher increase (2.0 log(10) CFU/g of stool) as compared to cefepime (1.7 log(10) CFU/g of stool). However, these increases were statistically not significant. CONCLUSION: Cefepime and meropenem when given to sensitive patients do not increase significantly the risk of Candida infection originating in the GI tract. Copyright 2001 S. Karger AG, Basel

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017